Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal
Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.
You may also be interested in...
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Janssen Biotech has won FDA approval for Genmab-licensed Darzalex in newly diagnosed multiple myeloma. However, the drug was approved in a combination that is not commonly used in the US. A further label expansion will provide a bigger boost to the anti-CD38 antibody's commercial prospects.
The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.